1010 patients post stenting were enrolled to receive Plavix more than 12 months and less than that and rate of bleeding, complication and major cardiovascular adverse events ( MACE) were compared to evaluate safety and feasibility of long term Plavix therapy post stenting.

1010 patients from registry of angioplasty and stenting in Shiraz and Baghiatolah hospital were enrolled and long term Plavix therapy more than and less than 12 months were compared between two groups of patients prospectively and rate of major adverse cardiovascular events ( MACE) (death, myocardial infarction, cerebrovascular accidents and revascularization) and rate of bleeding were compared between 2 groups.Syntax score and American heart association ( AHA) score of coronary involvement were measured and MACE was compared to these scores.

Inclusion Criteria:

• post stent ( lesion more than 70% and vessel more than 2.25 mm )

Exclusion Criteria:

• allergy to acetylsalicylic acid or clopidogrel,
• planned surgery within 24 months of percutaneous coronary intervention unless the dual antiplatelet therapy could be maintained throughout the perisurgical period
• history of bleeding diathesis
• major surgery within 15 days
• active bleeding
• previous stroke in the past 6 months
• concomitant or foreseeable need for oral anticoagulation therapy
• pregnancy, life expectancy <24 months, participation in another trial
• inability to provide informed consent